NCT07644559Phase 2Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Study sponsor: Verastem, Inc. · VSTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants185Estimated
Source updated2026-11-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 5 participants

Before: 180 participants (planned). After: 185 participants (planned).

Check registry source